Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Current Portion of Long-Term Debt
Zealand Pharma A/S
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Current Portion of Long-Term Debt
kr16m
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Genmab A/S
CSE:GMAB
|
Current Portion of Long-Term Debt
kr92m
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Current Portion of Long-Term Debt
€458.2m
|
CAGR 3-Years
303%
|
CAGR 5-Years
139%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Current Portion of Long-Term Debt
kr41.5m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
36%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Current Portion of Long-Term Debt
kr3.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
67%
|
|
|
Saniona AB
STO:SANION
|
Current Portion of Long-Term Debt
kr10.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
16m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Current Portion of Long-Term Debt amounts to 16m DKK.
What is Zealand Pharma A/S's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
12%
Over the last year, the Current Portion of Long-Term Debt growth was -4%. The average annual Current Portion of Long-Term Debt growth rates for Zealand Pharma A/S have been 2% over the past three years , 16% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet